<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03206671</url>
  </required_header>
  <id_info>
    <org_study_id>UKM12_0020</org_study_id>
    <secondary_id>2013-003253-21</secondary_id>
    <nct_id>NCT03206671</nct_id>
  </id_info>
  <brief_title>Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents</brief_title>
  <acronym>B-NHL 2013</acronym>
  <official_title>B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial B-NHL 2013 is a collaborative prospective, multi-national, multi-center, randomized
      trial with participating centers of the NHL-BFM group (Austria, Switzerland, Czech Republic,
      Germany) and the Scandinavian NOPHO group (Denmark, Finland, Norway, Sweden). The aim of the
      trial is to evaluate the role of rituximab in the treatment of mature aggressive B-cell
      Non-Hodgkin lymphoma and leukemia (B-NHL and B-AL) in children and adolescents.

      The following primary study questions are going to be analyzed:

        -  the effectiveness (event-free survival) in pediatric patients with very limited mature
           B-NHL (R1 and R2 stage I and II) of substituting anthracyclines by the rituximab window
           without compromising survival rates.

        -  the effectiveness (event-free survival) in pediatric patients with limited mature B-NHL
           (R2 stage III) randomly assigned to receive the rituximab window plus standard
           chemotherapy or standard chemotherapy without the rituximab window.

        -  the effectiveness (event-free survival) and the immune reconstitution (recovery of CD19+
           B-cells, IR) in pediatric patients with advanced mature B-NHL/B-AL (R3 and R4 incl. R4
           CNS+) treated with BFM-type chemotherapy and randomly assigned schedules of one versus
           seven doses rituximab.

      Secondary study questions will address

        -  additional parameters for immune reconstitution, lymphocyte subpopulations,
           immunoglobulin levels, vaccination titers and infection rates

        -  kinetics of immune reconstitution after treatment

        -  adverse event and severe adverse event profile

        -  inter-individual variability of rituximab response

        -  role of different mechanisms of action of rituximab in advanced B-NHL/B-AL
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Risk group stratification:

      R1/R2 stage I+II:

        -  R1: resection status: complete

        -  R2: resection status: incomplete, stage I and II

      R2 III:

      - R 2: resection status: incomplete, stage III and LDH &lt; 2 x ULN (according to local
      reference value for adults)

      R3/R4:

        -  R3: resection status: incomplete, stage III and LDH ≥ 2 x ULN but &lt; 4 x ULN or stage
           IV/B-AL and LDH &lt; 4 x ULN and CNS negative

        -  R4: resection status: incomplete, Stage III and LDH ≥ 4 x ULN or stage IV/B-AL and LDH ≥
           4 x ULN and CNS negative

        -  R4 CNS +: stage IV/B-AL and CNS positive

      For patients with very limited disease (R1/R2 stage I/II), the addition of rituximab might
      allow the omission of anthracyclines without jeopardizing survival rates but reducing acute
      and long term toxicities. In this treatment arm, it is tested whether the event-free survival
      is similar to that of the historical control when all patients receive one dose of rituximab
      as monotherapeutic agent in the rituximab window R five days prior to the start of standard
      chemotherapy as a substitute for anthracyclines.

      For patients with limited disease (R2 stage III) it is tested whether the event-free survival
      can be improved by adding rituximab to the standard chemotherapy. Two different treatment
      regimens will be evaluated in a randomized design: Patients in the standard arm will receive
      the standard chemotherapy. Patients of the rituximab plus arm will receive one dose of
      rituximab as monotherapeutic agent in the rituximab window R five days prior to the start of
      standard chemotherapy.

      For patients with advanced disease (R3/R4) it is tested whether the event-free survival can
      be improved by adding rituximab to the standard chemotherapy. Two different rituximab
      regimens will be evaluated in a randomized design: Patients in the standard arm will receive
      one dose of rituximab as monotherapeutic agent in the rituximab window R five days prior to
      the start of standard chemotherapy. Patients of the rituximab plus arm will receive the
      rituximab window and additional six doses of rituximab added to the first four courses of
      chemotherapy. In addition the immune reconstitution will be analyzed comparing the effect of
      the two regimens of rituximab added to standard chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2017</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>through study completion, maximal seven years</time_frame>
    <description>EFS is defined as time from start of treatment/randomization up to event or to date of last contact for patients without event. The following occurrences are defined as an event: non-response, progressive disease or relapse, treatment related death, death of any other cause or diagnosis of secondary malignancies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune reconstitution rate (only in R3/R4 patients)</measure>
    <time_frame>12 months after start of treatment</time_frame>
    <description>Immune reconstitution rate is defined as percentage of patients achieving age adjusted normal B-cell counts (CD19 positive subpopulations) 12 months after start of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>through study completion, maximal seven years</time_frame>
    <description>OS is defined as time from start of treatment/randomization up to death of any cause or to date of last contact for patients alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>through study completion, maximal seven years</time_frame>
    <description>RFS is defined as time from start of treatment/randomization up to event or to date of last contact for patients without event. The following occurrences are defined as an event: non-response, progressive disease, or relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>after rituximab window on day 5, after prephase (patients with rituximab window on day 10, patients without rituximab window on day 6) and after second course (on an average 5 to 6 weeks after start of treatment)</time_frame>
    <description>Complete response, partial remission, objective effect, stable disease or progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>from the first day of protocol defined treatment until two years after start of protocol defined treatment</time_frame>
    <description>Rate of patients with acute toxicity defined as grade III/IV/V AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients achieving normal immunoglobulin level 12 months after start of treatment</measure>
    <time_frame>12 months after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time interval to normal immunoglobulin level</measure>
    <time_frame>through study completion, maximal seven years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time interval from start of treatment to normal CD19 positive B-cells in the peripheral blood.</measure>
    <time_frame>through study completion, maximal seven years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with normal lymphocyte subpopulations in the peripheral blood 12 months after start of treatment</measure>
    <time_frame>12 months after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interval to normal lymphocyte subpopulations in the peripheral blood.</measure>
    <time_frame>through study completion, maximal seven years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infections (defined by CTCAE V4) in the time interval from start of treatment until 24 months after start of treatment</measure>
    <time_frame>24 months after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infections (defined by CTCAE V4) in the time interval from start of treatment until immune reconstitution (achievement of age adjusted normal B-cell counts)</measure>
    <time_frame>through study completion, maximal seven years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with sufficient titers after vaccination one year after start of treatment</measure>
    <time_frame>1 year after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution rate (only in R1/R2 patients)</measure>
    <time_frame>12 months after start of treatment</time_frame>
    <description>Immune reconstitution rate is defined as percentage of patients achieving age adjusted normal B-cell counts (CD19 positive subpopulations) 12 months after start of treatment.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Mature B-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>R1/R2 stage I+II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab window + standard chemotherapy without anthracyclines (Vincristine not in R1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2 stage III experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab window + Standard chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2 stage III standard arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab window + standard chemotherapy plus six additional doses of rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R3/R4 standard arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab window + standard chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab window</intervention_name>
    <description>Rituximab window (375 mg/m²)</description>
    <arm_group_label>R1/R2 stage I+II</arm_group_label>
    <arm_group_label>R2 stage III experimental arm</arm_group_label>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
    <arm_group_label>R3/R4 standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Additional doses of Rituximab</intervention_name>
    <description>2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle</description>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>see detailed protocol description</description>
    <arm_group_label>R1/R2 stage I+II</arm_group_label>
    <arm_group_label>R2 stage III experimental arm</arm_group_label>
    <arm_group_label>R2 stage III standard arm</arm_group_label>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
    <arm_group_label>R3/R4 standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>see detailed protocol description</description>
    <arm_group_label>R1/R2 stage I+II</arm_group_label>
    <arm_group_label>R2 stage III experimental arm</arm_group_label>
    <arm_group_label>R2 stage III standard arm</arm_group_label>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
    <arm_group_label>R3/R4 standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>see detailed protocol description</description>
    <arm_group_label>R1/R2 stage I+II</arm_group_label>
    <arm_group_label>R2 stage III experimental arm</arm_group_label>
    <arm_group_label>R2 stage III standard arm</arm_group_label>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
    <arm_group_label>R3/R4 standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin hydrochloride</intervention_name>
    <description>see detailed protocol description</description>
    <arm_group_label>R2 stage III experimental arm</arm_group_label>
    <arm_group_label>R2 stage III standard arm</arm_group_label>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
    <arm_group_label>R3/R4 standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vindesine Sulfate</intervention_name>
    <description>see detailed protocol description</description>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
    <arm_group_label>R3/R4 standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>see detailed protocol description</description>
    <arm_group_label>R1/R2 stage I+II</arm_group_label>
    <arm_group_label>R2 stage III experimental arm</arm_group_label>
    <arm_group_label>R2 stage III standard arm</arm_group_label>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
    <arm_group_label>R3/R4 standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>see detailed protocol description</description>
    <arm_group_label>R1/R2 stage I+II</arm_group_label>
    <arm_group_label>R2 stage III experimental arm</arm_group_label>
    <arm_group_label>R2 stage III standard arm</arm_group_label>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
    <arm_group_label>R3/R4 standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>see detailed protocol description</description>
    <arm_group_label>R1/R2 stage I+II</arm_group_label>
    <arm_group_label>R2 stage III experimental arm</arm_group_label>
    <arm_group_label>R2 stage III standard arm</arm_group_label>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
    <arm_group_label>R3/R4 standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>see detailed protocol description</description>
    <arm_group_label>R1/R2 stage I+II</arm_group_label>
    <arm_group_label>R2 stage III experimental arm</arm_group_label>
    <arm_group_label>R2 stage III standard arm</arm_group_label>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
    <arm_group_label>R3/R4 standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>see detailed protocol description</description>
    <arm_group_label>R1/R2 stage I+II</arm_group_label>
    <arm_group_label>R2 stage III experimental arm</arm_group_label>
    <arm_group_label>R2 stage III standard arm</arm_group_label>
    <arm_group_label>R3/R4 rituximab plus arm</arm_group_label>
    <arm_group_label>R3/R4 standard arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed, histological or cytological and immunological proven aggressive
             mature B-cell Non-Hodgkin lymphoma including Burkitt lymphoma (BL), Burkitt leukemia
             (B-AL), diffuse large B-cell lymphoma (DLBCL), or mature B-cell NHL not further
             classified according to current WHO classification. For rare subtypes (e.g. primary
             mediastinal large B-NHL, PMLBL), consultation of the study center is recommended.

          -  availability of slides/blocks for reference pathology and international pathology
             panel (except in cases with immunological and cytomorphological assurance of
             diagnosis)

          -  age at diagnosis &lt; 18 years

          -  diagnostics and treatment in one of the participating centers of the trial

          -  no previous chemotherapy, no previous lymphoma-directed treatment. No application of
             steroids for more than two days during the last month

          -  adequate hepatic, renal and cardiac function, except if alteration is due to lymphoma
             infiltration

          -  signed informed consent of patient and/or parents/guardians for participation and
             transfer of data

          -  follow-up of at least two years after initial diagnosis is expected

          -  Certificate of vaccination against hepatitis B or negative serology, defined as

               -  evidence of immunization with HBs-antigen negative, anti-HBs positive and
                  anti-HBc negative or

               -  negative hepatitis B serology with HBs-antigen negative, anti-HBs and anti- HBc
                  negative

        Exclusion Criteria:

          -  patients with insufficient work up not allowing a correct stratification into the risk
             groups

          -  B-cell neoplasia as second malignancy

          -  any other medical, psychiatric or social condition prohibiting treatment according to
             the protocol (e.g. previous malignancy, prior organ transplant, HIV infection or AIDS
             or severe immunodeficiency, etc.)

          -  participation within a different trial for treatment of B-cell malignancies and/or
             concurrent treatment within any other clinical trial. Exceptions to this are the
             NHL-BFM Registry 2012 and trials with different endpoints, involving aspects of
             supportive treatment which can run parallel to B-NHL 2013 without influencing the
             outcome of this trial e.g. trials on antiemetics, antibiotics, strategies for
             psychosocial support etc.

          -  overt hepatitis B or history of hepatitis B

          -  hypersensitivity to rituximab or to murine proteins or to any of the other excipients
             of the Investigational Medicinal Product rituximab (MabThera®) or to ingredients of
             other IMPs.

          -  lack of CD20 expression of the lymphoma cells

          -  pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birgit Burkhardt, Prof. Dr. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Muenster, Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Birgit Burkhardt, Prof. Dr. Dr.</last_name>
    <phone>+49 251 83 55696</phone>
    <email>b-nhl2013@ukmuenster.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univ.Klinik für Kinder- und Jugendheilkunde Graz, Klin. Abteilung für pädiatrische Hämato-Onkologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ.Klinik für Kinder- und Jugendheilkunde Innsbruck, Universitätsklinik für Pädiatrie I</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt am Wörthersee, Abteilung für Kinder- und Jugendheilkunde</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LKH Leoben, Abteilung für Kinder- und Jugendheilkunde</name>
      <address>
        <city>Leoben</city>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum, Med Campus IV / Onkologie</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LKH Salzburg, Universitätsklinik für Kinder- und Jugendheilkunde, Kinderonkologie</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Anna Kinderspital</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Oncology, University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>662 63</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Hematology and Oncology, University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Børneonkologisk afsnit 303B, Børneafdelingen, Aalborg Universitetshospital Nord</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Børn og Unge afsnit 4, Børneafdelingen, Aarhus Universitetshospital Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>8200 N</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Børneonkologisk afsnit 5054, BørneUngeKlinikken, Juliane Marie Centret, Rigshospitalet</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2100 Ø</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Børneonkologisk afsnit H2, H. C. Andersen Børnehospital, Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <zip>5000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital, Children´s Hospital, Dept of Pediatric Hematology and Oncology</name>
      <address>
        <city>Helsinki</city>
        <zip>00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital, Paediatric Haematology and Oncology</name>
      <address>
        <city>Kuopio</city>
        <zip>70029 KYS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Oulu, Paediatric Haematology and Oncology</name>
      <address>
        <city>Oulu</city>
        <zip>90029 OYS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital, Paediatric Haematology and Oncology</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital, Paediatric and Adolescent Haematology and Oncology</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, Klinik für Kinder - und Jugendmedizin, Hämatologie / Onkologie</name>
      <address>
        <city>Aachen</city>
        <zip>52057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg, Schwäbisches Kinderkrebszentrum, I. Klinik für Kinder und Jugendliche, Hämatologie / Onkologie</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum, Zentrum für Kinder- und Jugendmedizin, Abt. Hämatologie / Onkologie</name>
      <address>
        <city>Berg</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch, Kinderklinik, Pädiatrische Hämatologie und Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Bielefeld GmbH, Klinik für Kinder- und Jugendmedizin, Hämatologie und Onkologie</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zentrum für Kinderheilkunde der Universität Bonn, Abt. Päd. Hämatologie / Onkologie</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig gGmbH, Klinik für Kinder- und Jugendmedizin, Station K5 / Päd. Hämato- und Onkologie</name>
      <address>
        <city>Braunschweig</city>
        <zip>38118</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH, Prof.-Hess-Kinderklinik,Pädiatrische Onkologie und Hämatologie</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH, Klinik für Kinder- und Jugendmedizin, Päd. Hämatologie und Onkologie</name>
      <address>
        <city>Chemnitz</city>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vestische Kinderklinik, Universität Witten / Herdecke</name>
      <address>
        <city>Datteln</city>
        <zip>45711</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund gGmbH, Klinik für Kinder- und Jugendmedizin, Station K1, Abt. Päd. Onkologie / Hämatologie</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Carl Gustav Carus der TU Dresden, Klinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Zentrum für Kinder- und Jugendmedizin, Klinik für Päd. Hämatologie und Onkologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Erfurt GmbH, Klinik für Kinder- und Jugendmedizin, Päd. Onkologie / Hämatologie</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Klinik für Kinder- und Jugendmedizin, Pädiatrische Onkologie / Hämatologie</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Zentrum für Kinder- und Jugendmedizin, Hämatologie / Onkologie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Zentrum für Kinder- und Jugendmedizin, Klinik IV: Päd. Hämatologie und Onkologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg, Standort Gießen, Zentrum für Kinderhämatologie und -onkologie</name>
      <address>
        <city>Gießen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Greifswald KdöR, Klinik und Poliklinik für Kinder- und Jugendmedizin, Abt. Pädiatrische Onkologie und Hämatologie</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georg-August-Universität Universitäts-Kinderklinik, Pädiatrie I</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale), Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie / Onkologie</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf, Zentrum für Kinder- und Jugendmedizin, Abt. Pädiatrische Hämatologie und Onkologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Kinderheilkunde, Päd. Hämatologie / Onkologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik Heidelberg, Abt. Hämatologie / Onkologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftskrankenhaus Herdecke, Kinder- und Jugendmedizin, Päd. Hämatologie / Onkologie</name>
      <address>
        <city>Herdecke</city>
        <zip>58313</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken für Kinder- und Jugendmedizin, Päd. Hämatologie und Onkologie, Geb. 9</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Jena</city>
        <zip>07745</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe gGmbH, Kinderklinik, Station S 24</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel Gesundheit Nordhessen Holding AG, Klinik für pädiatrische Hämatologie und Onkologie</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig Holstein Campus Kiel, Klinik für Allgemeine Pädiatrie, Päd. Onkologie / Hämatologie</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Krefeld, Zentrum für Kinder- und Jugendmedizin, Päd. Hämatologie/Onkologie</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität zu Köln, Klinik für Kinder- und Jugendmedizin, Abt. Kinderonkologie und -hämatologie</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Klinik für Kinder und Jugendliche, Abt. Päd. Hämatologie / Onkologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig Holstein Campus Lübeck, Klinik für Kinder- und Jugendmedizin, Hämatologie und Onkologie</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg A. ö. R., Kinderklinik, Päd. Hämatologie / Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Zentrum für Kinder- und Jugendmedizin, Pädiatrische Hämatologie / Onkologie</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim gGmbH, Universitäts-Kinderklinik, Päd. Onkologie /Hämatologie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden, Klinik für Kinder- und Jugendmedizin, Päd. Hämatologie / Onkologie, Station E 22</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der LMU, Dr. von Haunersches Kinderspital, Pädiatrische Hämatologie / Onkologie</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwabing, Kinderklinik der TU Päd. Hämatologie / Onkologie, Station 24d</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Kinder- und Jugendmedizin, Abt. Pädiatrische Hämatologie und Onkologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diakonie Neuendettelsau, Kliniken Hallerwiese / Cnopf'sche Kinderklinik, Pädiatrische Hämatologie /Onkologie</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg AöR, Zentrum für Kinder- und Jugendmedizin, Abt. Hämatologie / Onkologie</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik für Kinder- und Jugendmedizin, Abt. Päd. Hämatologie, Onkologie, SZT</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock, Kinder- und Jugendklinik, Päd. Hämatologie und Onkologie</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Augustin GmbH, Kinder- und Jugendmedizin, Kinder-Hämatologie und Onkologie</name>
      <address>
        <city>Sankt Augustin</city>
        <zip>53757</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Kliniken Schwerin GmbH, Klinik für Kinder- und Jugendmedizin, Station A1</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Olgahospital Zentrum für Kinder- und Jugendmedizin Pädiatrie 5 (Onkologie, Hämatologie, Immunologie)</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromäerinnen gGmbH, Pädiatrische Abteilung</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Tübingen Klinik für Kinderheilkunde und Jugendmedizin, Päd. Hämatologie / Onkologie</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik für Kinder- und Jugendmedizin, Päd. Hämatologie und Onkologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätskinderklinik Würzburg, Päd. Onkologie und Hämatologie</name>
      <address>
        <city>Würzburg</city>
        <zip>907080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital, National Study Center Norway</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Northern Norway</name>
      <address>
        <city>Tromsø</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset, Drottning Silvias Barn och Ungdomssjukhus, Barncancercentrum</name>
      <address>
        <city>Göteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset i Linköping, Barn och Ungdomsmedicinska kliniken, Barnonkologiska enheten</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skåne Universitetssjukhus, Barnonkologi</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset, Astrid Lindgrens Barnsjukhus, Barnonkologen</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhus Umeå, Barnonkologiska avdelningen, Barn 3 Norrlands</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset, Barnavdelningen för blod- och tumörsjukdomar</name>
      <address>
        <city>Uppsala</city>
        <zip>752 39</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau, Kinderklinik</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitäts - Kinderspital beider Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni, Reparto die Pediatria</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Kinderheilkunde, Pädiatrische Hämatologie/ Onkologie, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants, Unité d'Oncologie Hématologie</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire vaudois, Unité d'hémato-oncologie pédiatrique</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinderspital Pädiatrische Hämatologie/ Onkologie</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ostschweizer Kinderspital, Hämatologie/ Onkologie</name>
      <address>
        <city>Saint Gallen</city>
        <zip>9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderspital, Pädiatrische Onkologie</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Vindesine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

